Bombesin prevents gastric injury in the rat: Role of gastrin

David W. Mercer, James M. Cross, Lily Chang, Lenard M. Lichtenberger

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Bombesin or gastrin-releasing peptide prevents gastric injury by an unknown mechanism. Since exogenous gastrin is a gastroprotective agent, this study was undertaken to test the hypothesis that gastroprotection by bombesin involves release of endogenous gastrin. Subcutaneous bombesin (10-100 μg/kg) dose dependently reduced macroscopic injury to the acid-secreting portion of the stomach caused by 1 ml of orogastric acidified ethanol (150 mM hydrochloric acid-50% ethanol). Blockade of type A cholecystokinin receptors with intraperitoneal MK-329 (1 mg/kg) reversed intravenous cholecystokinin (5 nmol/kg)-induced gastroprotection, but not that of bombesin. In contrast, intraperitoneal type B cholecystokinin (gastrin) receptor blockade with L- 365,260 (25 mg/kg) diminished the protective actions of both subcutaneous bombesin (100 μg/kg) and intravenous gastrin (25 pmol/kg). In additional studies, subcutaneous bombesin (10-100 μg/kg) dose dependently increased serum gastrin levels (radioimmunoassay). Both the gastroprotective actions of bombesin and bombesin-induced gastrin release were enhanced following immunoneutralization of endogenous somatostatin with intraperitoneal somatostatin antibody (2 mg). These data indicate that bombesin prevents gastric injury primarily by release of endogenous gastrin and both effects are modified by endogenous somatostatin.

Original languageEnglish (US)
Pages (from-to)826-833
Number of pages8
JournalDigestive Diseases and Sciences
Volume43
Issue number4
DOIs
StatePublished - Apr 29 1998

Fingerprint

Bombesin
Gastrins
Stomach
Wounds and Injuries
Somatostatin
Ethanol
Devazepide
Cholecystokinin A Receptor
Gastrin-Releasing Peptide
Cholecystokinin B Receptor
Cholecystokinin Receptors
Hydrochloric Acid
Cholecystokinin
Radioimmunoassay
Acids
Antibodies

Keywords

  • Bombesin
  • Cholecystokinin
  • Gastric injury
  • Gastrin
  • Somatostatin

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Cite this

Bombesin prevents gastric injury in the rat : Role of gastrin. / Mercer, David W.; Cross, James M.; Chang, Lily; Lichtenberger, Lenard M.

In: Digestive Diseases and Sciences, Vol. 43, No. 4, 29.04.1998, p. 826-833.

Research output: Contribution to journalArticle

Mercer, David W. ; Cross, James M. ; Chang, Lily ; Lichtenberger, Lenard M. / Bombesin prevents gastric injury in the rat : Role of gastrin. In: Digestive Diseases and Sciences. 1998 ; Vol. 43, No. 4. pp. 826-833.
@article{f3c88ca864f74e0ca0452328cf22bfda,
title = "Bombesin prevents gastric injury in the rat: Role of gastrin",
abstract = "Bombesin or gastrin-releasing peptide prevents gastric injury by an unknown mechanism. Since exogenous gastrin is a gastroprotective agent, this study was undertaken to test the hypothesis that gastroprotection by bombesin involves release of endogenous gastrin. Subcutaneous bombesin (10-100 μg/kg) dose dependently reduced macroscopic injury to the acid-secreting portion of the stomach caused by 1 ml of orogastric acidified ethanol (150 mM hydrochloric acid-50{\%} ethanol). Blockade of type A cholecystokinin receptors with intraperitoneal MK-329 (1 mg/kg) reversed intravenous cholecystokinin (5 nmol/kg)-induced gastroprotection, but not that of bombesin. In contrast, intraperitoneal type B cholecystokinin (gastrin) receptor blockade with L- 365,260 (25 mg/kg) diminished the protective actions of both subcutaneous bombesin (100 μg/kg) and intravenous gastrin (25 pmol/kg). In additional studies, subcutaneous bombesin (10-100 μg/kg) dose dependently increased serum gastrin levels (radioimmunoassay). Both the gastroprotective actions of bombesin and bombesin-induced gastrin release were enhanced following immunoneutralization of endogenous somatostatin with intraperitoneal somatostatin antibody (2 mg). These data indicate that bombesin prevents gastric injury primarily by release of endogenous gastrin and both effects are modified by endogenous somatostatin.",
keywords = "Bombesin, Cholecystokinin, Gastric injury, Gastrin, Somatostatin",
author = "Mercer, {David W.} and Cross, {James M.} and Lily Chang and Lichtenberger, {Lenard M.}",
year = "1998",
month = "4",
day = "29",
doi = "10.1023/A:1018830517773",
language = "English (US)",
volume = "43",
pages = "826--833",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Bombesin prevents gastric injury in the rat

T2 - Role of gastrin

AU - Mercer, David W.

AU - Cross, James M.

AU - Chang, Lily

AU - Lichtenberger, Lenard M.

PY - 1998/4/29

Y1 - 1998/4/29

N2 - Bombesin or gastrin-releasing peptide prevents gastric injury by an unknown mechanism. Since exogenous gastrin is a gastroprotective agent, this study was undertaken to test the hypothesis that gastroprotection by bombesin involves release of endogenous gastrin. Subcutaneous bombesin (10-100 μg/kg) dose dependently reduced macroscopic injury to the acid-secreting portion of the stomach caused by 1 ml of orogastric acidified ethanol (150 mM hydrochloric acid-50% ethanol). Blockade of type A cholecystokinin receptors with intraperitoneal MK-329 (1 mg/kg) reversed intravenous cholecystokinin (5 nmol/kg)-induced gastroprotection, but not that of bombesin. In contrast, intraperitoneal type B cholecystokinin (gastrin) receptor blockade with L- 365,260 (25 mg/kg) diminished the protective actions of both subcutaneous bombesin (100 μg/kg) and intravenous gastrin (25 pmol/kg). In additional studies, subcutaneous bombesin (10-100 μg/kg) dose dependently increased serum gastrin levels (radioimmunoassay). Both the gastroprotective actions of bombesin and bombesin-induced gastrin release were enhanced following immunoneutralization of endogenous somatostatin with intraperitoneal somatostatin antibody (2 mg). These data indicate that bombesin prevents gastric injury primarily by release of endogenous gastrin and both effects are modified by endogenous somatostatin.

AB - Bombesin or gastrin-releasing peptide prevents gastric injury by an unknown mechanism. Since exogenous gastrin is a gastroprotective agent, this study was undertaken to test the hypothesis that gastroprotection by bombesin involves release of endogenous gastrin. Subcutaneous bombesin (10-100 μg/kg) dose dependently reduced macroscopic injury to the acid-secreting portion of the stomach caused by 1 ml of orogastric acidified ethanol (150 mM hydrochloric acid-50% ethanol). Blockade of type A cholecystokinin receptors with intraperitoneal MK-329 (1 mg/kg) reversed intravenous cholecystokinin (5 nmol/kg)-induced gastroprotection, but not that of bombesin. In contrast, intraperitoneal type B cholecystokinin (gastrin) receptor blockade with L- 365,260 (25 mg/kg) diminished the protective actions of both subcutaneous bombesin (100 μg/kg) and intravenous gastrin (25 pmol/kg). In additional studies, subcutaneous bombesin (10-100 μg/kg) dose dependently increased serum gastrin levels (radioimmunoassay). Both the gastroprotective actions of bombesin and bombesin-induced gastrin release were enhanced following immunoneutralization of endogenous somatostatin with intraperitoneal somatostatin antibody (2 mg). These data indicate that bombesin prevents gastric injury primarily by release of endogenous gastrin and both effects are modified by endogenous somatostatin.

KW - Bombesin

KW - Cholecystokinin

KW - Gastric injury

KW - Gastrin

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0031926410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031926410&partnerID=8YFLogxK

U2 - 10.1023/A:1018830517773

DO - 10.1023/A:1018830517773

M3 - Article

C2 - 9558040

AN - SCOPUS:0031926410

VL - 43

SP - 826

EP - 833

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 4

ER -